Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 16;319(3):266-278.
doi: 10.1001/jama.2017.20813.

Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study

Affiliations

Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study

Sayeed Ikramuddin et al. JAMA. .

Abstract

Importance: The Roux-en-Y gastric bypass is effective in achieving established diabetes treatment targets, but durability is unknown.

Objective: To compare durability of Roux-en-Y gastric bypass added to intensive lifestyle and medical management in achieving diabetes control targets.

Design, setting, and participants: Observational follow-up of a randomized clinical trial at 4 sites in the United States and Taiwan, involving 120 participants who had a hemoglobin A1c (HbA1c) level of 8.0% or higher and a body mass index between 30.0 and 39.9 (enrolled between April 2008 and December 2011) were followed up for 5 years, ending in November 2016.

Interventions: Lifestyle-intensive medical management intervention based on the Diabetes Prevention Program and LookAHEAD trials for 2 years, with and without (60 participants each) Roux-en-Y gastric bypass surgery followed by observation to year 5.

Main outcomes and measures: The American Diabetes Association composite triple end point of hemoglobin A1c less than 7.0%, low-density lipoprotein cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg at 5 years.

Results: Of 120 participants who were initially randomized (mean age, 49 years [SD, 8 years], 72 women [60%]), 98 (82%) completed 5 years of follow-up. Baseline characteristics were similar between groups: mean (SD) body mass index 34.4 (3.2) for the lifestyle-medical management group and 34.9 (3.0) for the gastric bypass group and had hemoglobin A1c levels of 9.6% (1.2) and 9.6% (1.0), respectively. At 5 years, 13 participants (23%) in the gastric bypass group and 2 (4%) in the lifestyle-intensive medical management group had achieved the composite triple end point (difference, 19%; 95% CI, 4%-34%; P = .01). In the fifth year, 31 patients (55%) in the gastric bypass group vs 8 (14%) in the lifestyle-medical management group achieved an HbA1c level of less than 7.0% (difference, 41%; 95% CI, 19%-63%; P = .002). Gastric bypass had more serious adverse events than did the lifestyle-medical management intervention, 66 events vs 38 events, most frequently gastrointestinal events and surgical complications such as strictures, small bowel obstructions, and leaks. Gastric bypass had more parathyroid hormone elevation but no difference in B12 deficiency.

Conclusions and relevance: In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement.

Trial registration: clinicaltrials.gov Identifier: NCT00641251.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ikramuddin serves as an advisory board member for Novo Nordisk, USGI, and Medica, consults for Metamodix, and receives grant support from Medtronic, ReShape Medical, and institutional support from Enteromedics. Dr Korner reported that she has received institutional grant support from Medtronic and the National Institutes of Health (NIH), serves on the Scientific Advisory Board of Digma Medical, and had served on the speaker’s bureau for Takeda. Ms Thomas reports that she received institutional grant support from Medtronic and the NIH. Dr Connett reported that he has received institutional grant support from Medtronic and the NIH, travel expenses and personal support from the US Food and Drug Administration advisory panel on pulmonary drugs, salary support from Medtronic for the Diabetes Surgery Study, and supplemental salary support from the Minnesota Obesity Center and that he is employed by Optum. Dr Leslie reported receiving grant support from Medtronic. Dr Jensen reported receiving grant support from Covidian and personal fees from Novo Nordisk. Dr Jensen reported receiving institutional grant support from Covidien and consulting support from Novo Nordisk, Eisai, Genentech, and Takeda. Dr Vella reported receiving consulting support from Genentech, Sanofi-Aventis, and Novartis; grant support from Biokier, Novartis, and GI Dynamics; personal fees from VTV therapeutics; and grants from XOMA. Dr Ahmed reported receiving institutional grant support from Medtronic. Dr Billington reported receiving institutional grant support from Medtronic, the NIH, and the Department of Veterans Affairs, and consulting support from Novo Nordisk, Enteromedics, and Optum. No other disclosures are reported.

Figures

Figure 1.
Figure 1.. Flow Diagram of Patients Through the Diabetes Surgery Study
BMI indicates body mass index, calculated as weight in kilograms divided by height in meters squared.
Figure 2.
Figure 2.. Outcomes Over Time
Point estimates represent fitted values from longitudinal mixed models. The 0 time point represents randomization. Error bars indicate 95% CI; LDL-C, low-density lipoprotein cholesterol (to convert from mg/dL to mmol/L, multiply by 0.0259). The P value for difference is .01.
Figure 3.
Figure 3.. Weight Loss Over Time
For Roux-en-Y gastric bypass, the 0 time point represents randomization. For both groups, blue indicates that the participant did not have bariatric surgery. Two patients were randomized to the Roux-en-Y gastric bypass group and are represented in blue based on their decision to decline surgery. Orange indicates that the participant did have bariatric surgery (as-treated basis). Some patients randomized to the intensive medical management group later obtained gastric bypass surgery outside of the study. They are reported on the intensive medical management graph (based on their randomization assignment), but their line turns from blue to orange at their approximate surgery date.

Comment in

References

    1. American Diabetes Association Standards of medical care in diabetes-2017 abridged for primary care providers. Clin Diabetes. 2017;35(1):5-26. - PMC - PubMed
    1. Lipska KJ, Krumholz HM. Is hemoglobin A1c the right outcome for studies of diabetes? JAMA. 2017;317(10):1017-1018. - PMC - PubMed
    1. American Diabetes Association Standards of medical care in diabetes--2008. Diabetes Care. 2008;31(suppl 1):S12-S54. - PubMed
    1. Purnell JQ, Selzer F, Wahed AS, et al. . Type 2 diabetes remission rates after laparoscopic gastric bypass and gastric banding: results of the longitudinal assessment of bariatric surgery study. Diabetes Care. 2016;39(7):1101-1107. - PMC - PubMed
    1. Mingrone G, Panunzi S, De Gaetano A, et al. . Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964-973. - PubMed

Publication types

Associated data